Techsomed

Company Overview

Snapshot

Founded in August 2012 by Yossi Abu, Techsomed operates with 11–50 employees. The company has raised $12.9 million across 6 funding rounds from 9 investors. In September 2025, Techsomed received U.S. FDA 510(k) clearance for its BioTraceIO360 software platform, expanding its indications to include percutaneous ablation of soft tissue in the kidney.

Business overview

Techsomed specializes in leveraging generative AI to enhance ablation therapy, a minimally invasive technique used for treating tumors, heart arrhythmias, and chronic pain. Its flagship product, the BioTraceIO360 software suite, integrates standard medical imaging modalities such as Ultrasound, CT, and MRI to provide physicians with tissue damage prediction, advanced patient-specific treatment planning, and interactive ablation procedure analysis. The company primarily serves the healthcare market, operating within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Medical Decision Support for providers globally, with subsidiaries in Germany and Japan supporting R&D and commercialization.

Strategic signal

In October 2025, Techsomed announced a pilot collaboration with Medtronic to integrate its BioTraceIO360 software with Medtronic's Emprint microwave ablation system. This partnership is significant as it aims to improve the precision of image-guided ablation therapy by offering interventional radiologists advanced real-time visualization and predictive margin control. This collaboration signals strong market validation for Techsomed's AI-powered platform and its potential to set new standards in minimally invasive ablation treatment, indicating a positive trajectory for commercial expansion and technological adoption.

Company Intelligence Q&A

What was a key regulatory milestone for Techsomed in 2025?

In September 2025, Techsomed received U.S. FDA 510(k) clearance for its BioTraceIO360 software platform, expanding its indications to include percutaneous ablation of soft tissue in the kidney. This builds on its previous liver application approval.

What strategic partnership did Techsomed announce in late 2025?

In October 2025, Techsomed announced a pilot collaboration with Medtronic to integrate its BioTraceIO360 software with Medtronic's Emprint microwave ablation system, aiming to enhance image-guided ablation therapy.

What significant executive appointment did Techsomed make in 2024?

In September 2024, Techsomed appointed Robert E. Gerberich as Chief Commercial Officer and Head of North America. This appointment aims to accelerate the U.S. launch and global expansion of the company's AI-powered BioTraceIO software suite.

What major regulatory achievement did Techsomed secure in early 2024?

In January 2024, Techsomed's BioTrace Solution achieved De Novo Clearance from the FDA, making it the first ultrasound-based software for tissue response prediction in liver tumor ablation.

When did Techsomed secure its Series B financing round?

In March 2021, Techsomed closed a Series B equity financing round led by Axil Capital and including participation from.